$26.50 Million in Sales Expected for Keryx Biopharmaceuticals (KERX) This Quarter

Share on StockTwits

Analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to report sales of $26.50 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Keryx Biopharmaceuticals’ earnings, with the highest sales estimate coming in at $29.92 million and the lowest estimate coming in at $24.71 million. Keryx Biopharmaceuticals reported sales of $15.14 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 75%. The firm is expected to report its next quarterly earnings report on Thursday, July 26th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full year sales of $111.26 million for the current fiscal year, with estimates ranging from $105.12 million to $117.74 million. For the next financial year, analysts expect that the company will post sales of $182.00 million per share, with estimates ranging from $163.55 million to $228.05 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.18) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). The business had revenue of $21.75 million during the quarter, compared to analyst estimates of $21.80 million.

Several analysts have issued reports on KERX shares. BidaskClub upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, April 20th. HC Wainwright started coverage on Keryx Biopharmaceuticals in a research note on Thursday, June 28th. They set a “buy” rating and a $9.00 price objective on the stock. ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 21st. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research note on Tuesday, July 10th. Finally, Stifel Nicolaus restated a “hold” rating and set a $5.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Monday, June 25th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $6.70.

Shares of Keryx Biopharmaceuticals traded down $0.16, hitting $4.33, during trading on Wednesday, Marketbeat reports. The company’s stock had a trading volume of 385,212 shares, compared to its average volume of 1,631,318. The company has a debt-to-equity ratio of -3.96, a quick ratio of 1.87 and a current ratio of 2.66. Keryx Biopharmaceuticals has a fifty-two week low of $3.30 and a fifty-two week high of $8.07. The stock has a market cap of $541.16 million, a price-to-earnings ratio of -4.92 and a beta of 2.65.

A number of hedge funds and other institutional investors have recently made changes to their positions in KERX. Teacher Retirement System of Texas acquired a new stake in shares of Keryx Biopharmaceuticals during the 4th quarter worth approximately $142,000. MetLife Investment Advisors LLC acquired a new stake in shares of Keryx Biopharmaceuticals during the 4th quarter worth approximately $187,000. Cornerstone Capital Management Holdings LLC. acquired a new stake in shares of Keryx Biopharmaceuticals during the 4th quarter worth approximately $192,000. Russell Investments Group Ltd. acquired a new stake in shares of Keryx Biopharmaceuticals during the 1st quarter worth approximately $201,000. Finally, Meridian Wealth Management LLC acquired a new stake in shares of Keryx Biopharmaceuticals during the 1st quarter worth approximately $203,000. Hedge funds and other institutional investors own 61.61% of the company’s stock.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Featured Story: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply